BioLineRx Ltd. (BLRX)

Market Cap	122.88M
Revenue (ttm)	n/a
Net Income (ttm)	-52.46M
Shares Out	72.23M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	255,142
Open	1.69
Previous Close	1.65
Day's Range	1.64 - 1.75
52-Week Range	0.55 - 2.53
Beta	1.10
Analysts	Strong Buy
Price Target	12.50 (+635.29%)
Earnings Date	Nov 20, 2023

About BLRX

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infection...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX

Analyst Forecast

According to 2 analysts, the average rating for BLRX stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 635.29% from the latest price.

Price Target

$12.5

(635.29% upside)

Analyst Consensus: Strong Buy